SYSung-Sik Yoo

Sung-Sik Yoo

*This is an algorithmically generated author record based on publicly available information.

Sung-Sik Yoo has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel Thermostabilizing Formulation for Enhanced Stability of Foot-and-Mouth Disease Virus During Storage and Environmental Stress

    by Mi-Kyeong Ko, Yoon-Hee Lee, Su-Mi Kim, I-Ryeong Yang, Tae-Jun Kim, Sung-Han Park, Jong-Hyeon Park, Saekil Yun, Seokin Yoon, Sung-Sik Yoo, et al.

    Among the seven-foot-and-mouth disease virus (FMDV) serotypes, serotype O is relatively thermolabile, posing significant challenges for virus preservation and vaccine manufacturing. Therefore, this study aimed to develop an effective thermostabilizing formulation to enhance the thermal stability of thermolabile FMDV serotype O strains, thereby facilitating their long-term storage. The stabilizing effect of a newly developed stabilizer, designated CVS, was assessed using two Korean field isolates (O/SKR/Jincheon/2014 and O/SKR/Boeun/2017) and two recombinant strains [O1 Manisa (R) and O PanAsia-2 (R)]. CVS was compared with conventional stabilizers consisting of 3% sucrose and 10% glycerol. Viral seed stocks were stored at −80 °C, 4 °C, 25 °C and 37 °C for 2, 4, and 7 d or subjected to accelerated stress conditions, after which viral thermostability was comparatively evaluated. Although 3% sucrose provided moderate protection, the CVS formulation demonstrated significantly superior stabilizing efficacy on viral infectivity, particularly under high-temperature stress conditions (25 °C and 37 °C) and during freeze–thaw cycles. However, the stabilizing effect varied among strains, suggesting strain-dependent differences in physicochemical properties and structural stability. Overall, CVS improved FMDV infectivity stability across a broad temperature range and exhibited greater protective efficacy than 3% sucrose, supporting its potential as an effective FMDV stabilizer.

  • Open Access

    Evaluation of the vaccine candidate ASFV-MEC-01: safety, efficacy, transmission dynamics, and assessment of reversion to virulence

    by Long Hoang Tran, Anh Ngoc Bui, Hyeok-Il Kwon, Tung Duy Dao, Asela Weerawardhana, Trang Mai Tran, Hoa Thi Vu, Quy Duy Nguyen, Nuwan Gamage, Min Ho Kim, et al.

    African swine fever (ASF) is a highly contagious and often fatal disease that poses a serious threat to global pig farming and food security. Despite decades of research, a safe and effective vaccine has not yet been widely implemented. In our previous study, we introduced ASFV-MEC-01, a novel live attenuated vaccine candidate developed through serial passaging of a field isolate in CA-CAS-01-A cells and subsequently characterized. In the present study, we further evaluated the safety parameters of ASFV-MEC-01. Specifically, we reaffirmed the safety and protective efficacy of ASFV-MEC-01 against a highly virulent Vietnamese ASFV strain. Notably, safety assessments were also conducted in pregnant sows. Furthermore, ASFV-MEC-01 showed no evidence of horizontal transmission to sentinel pigs and did not revert to virulence after consecutive in vivo passages, confirming its phenotypic stability. The vaccine also induced a sustained immune response in vaccinated pigs. Collectively, these findings demonstrate that ASFV-MEC-01 is a promising and safe live attenuated vaccine candidate, offering a valuable tool for effective ASF control.


  • Open Access

    Development of a Multiplex Conventional PCR Assay for Concurrent Detection of FAdV-4, FAdV-8b, and FAdV-11

    by Su-Kyung Kang, Dam-Hee Park, Kyeongcheol Min, Sung-Sik Yoo, In-Joong Yoon, Jongseo Mo

    Fowl adenovirus (FAdV) belongs to the Aviadenovirus genus within the Adenoviridae family. FAdVs are widely distributed and associated with various diseases in poultry, including adenoviral gizzard erosion (AGE), hepatitis-hydropericardium syndrome (HHS), and inclusion body hepatitis (IBH). In this study, we developed a multiplex conventional PCR for simultaneously detecting FAdV-4, -8b, and -11 by targeting the hexon gene. The multiplex PCR was optimized for primer concentrations and thermocycling conditions. The optimal primer concentration combination was set at 0.125 μM for FAdV-4, -8b, and 0.25 μM for FAdV-11. Under these conditions, the limit of detection (LOD) was 103 copies/μL of plasmid standards for FAdV-4, -8b, and -11. These results demonstrated that the developed multiplex PCR method exhibits high specificity and sensitivity, with no observed cross-reactivity among these serotypes or with other poultry viruses. Therefore, this multiplex PCR will be an effective tool for accurate serotyping of FAdV-4, -8b, and -11, enabling more precise identification and differentiation of these three serotypes.


  • Open Access

    Development and characterization of high-efficiency cell-adapted live attenuated vaccine candidate against African swine fever

    by Min Ho Kim, Ashan Subasinghe, Yongkwan Kim, Hyeok-Il Kwon, Yehjin Cho, Kiramage Chathuranga, Ji-Won Cha, Ji-Yoon Moon, Ji-Hyeon Hong, Jin Kim, et al.

    African swine fever (ASF), a contagious and lethal haemorrhagic disease of domestic pigs and wild boars, poses a significant threat to the global pig industry. Although experimental vaccine candidates derived from naturally attenuated, genetically engineered, or cell culture-adapted ASF virus have been tested, no commercial vaccine is accepted globally. We developed a safe and effective cell-adapted live attenuated vaccine candidate (ASFV-MEC-01) by serial passage of a field isolate in CA-CAS-01-A cells. ASFV-MEC-01, isolated via repeated plaque purification using next-generation sequencing analysis, was obtained at passage 18 and showed significant attenuation in 4- and 6-week-old pigs. ASFV-MEC-01 conferred 100% protection against challenge with lethal parental ASFV, which correlated with high ASFV-specific humoral and cellular immune responses. Additionally, ASFV-MEC-01 was not detected in blood until 28 days post-inoculation. Global transcriptome analysis showed that ASFV-MEC-01 lacking 12 genes triggered stronger innate antiviral responses than the parental virus, as exemplified by high levels of mRNA encoding interferon regulatory and inflammatory genes in PAM cells. Ectopic expression of most deleted genes increased replication of DNA viruses by suppressing production of interferons and pro-inflammatory cytokines. Among the genes deleted from ASFV-MEC-01, MGF100-1R interacted specifically with the scaffold dimerization domain of TBK1, thereby preventing TBK1 dimerization and impairing TBK1-mediated type I IFN and NF-κB signalling. These results suggest that attenuation of ASFV-MEC-01 may be mediated by induction of stronger type I IFN and NF-κB signalling within the host innate immune system. Thus, ASFV-MEC-01 could be a safe and effective live attenuated ASFV vaccine candidate with commercial potential.


  • Open Access

    CA-CAS-01-A: A Permissive Cell Line for Isolation and Live Attenuated Vaccine Development Against African Swine Fever Virus

    by Seung-Chul Lee, Yongkwan Kim, Ji-Won Cha, Kiramage Chathuranga, Niranjan Dodantenna, Hyeok-Il Kwon, Min Ho Kim, Weonhwa Jheong, In-Joong Yoon, Joo Young Lee, et al.

    African swine fever virus (ASFV) is the causative agent of the highly lethal African swine fever disease that affects domestic pigs and wild boars. In spite of the rapid spread of the virus worldwide, there is no licensed vaccine available. The lack of a suitable cell line for ASFV propagation hinders the development of a safe and effective vaccine. For ASFV propagation, primary swine macrophages and monocytes have been widely studied. However, obtaining these cells can be time-consuming and expensive, making them unsuitable for mass vaccine production. The goal of this study was to validate the suitability of novel CA-CAS-01-A (CAS-01) cells, which was identified as a highly permissive cell clone for ASFV replication in the MA-104 parental cell line for live attenuated vaccine development. Through a screening experiment, maximum ASFV replication was observed in the CAS-01 cell compared to other sub-clones of MA-104 with 14.89 and log10 7.5 ± 0.15 Ct value and TCID50/ml value respectively. When CAS-01 cells are inoculated with ASFV, replication of ASFV was confirmed by Ct value for ASFV DNA, HAD50/ml assay, TCID50/ml assay, and cytopathic effects and hemadsoption were observed similar to those in primary porcine alveolar macrophages after 5th passage. Additionally, we demonstrated stable replication and adaptation of ASFV over the serial passage. These results suggest that CAS-01 cells will be a valuable and promising cell line for ASFV isolation, replication, and development of live attenuated vaccines.


  • Open Access

    High-Level Expression of Recombinant VHSV Glycoprotein Using Transformed C. vulgaris and Verification of Vaccine Efficacy

    by Min-Jeong Kim, Seon-Young Kim, Ki-Hong Kim, Sung-Sik Yoo, Taek-Kyun Lee, Tae-Jin Choi

    The demand for aquaculture is increasing, but production is declining due to high feed costs and disease outbreaks. Viral hemorrhagic septicemia (VHS) is a viral disease that seriously affects seawater and freshwater fish in aquaculture, including the olive flounder (Paralichthys olivaceus), a major aquaculture fish in Korea. However, very few vaccines are currently available for viral hemorrhagic septicemia virus (VHSV). The nutrient-rich microalga Chlorella vulgaris has been used as a feed additive in aquaculture and as a host for the industrial production of recombinant VHSV glycoprotein as an oral vaccine. In this study, VHSV glycoprotein was cloned with a salt-inducible promoter, and high levels of expression up to 41.1 mg/g wet C. vulgaris, representing 27.4% of total extracted soluble protein, were achieved by growing the transformed C. vulgaris for 5 days in the presence of 250 mM NaCl. The production of a neutralizing antibody was detected in the serum of fish given feed containing 9% VHSV glycoprotein-expressing C. vulgaris. Furthermore, relative survival rates of 100% and 81.9% were achieved following challenges of these fish with VHSV at 106 and 107 pfu/fish, respectively, indicating that C. vulgaris could be used as a platform for the production of recombinant proteins for use as oral vaccines in the control of viral diseases in aquaculture.


  • Open Access

    Efficacy of a Novel Multiepitope Vaccine Candidate against Foot-and-Mouth Disease Virus Serotype O and A

    by W. A. Gayan Chathuranga, Chamith Hewawaduge, N. A. Nadeeka Nethmini, Tae-Hwan Kim, Ju Hun Kim, Young-Hoon Ahn, In-Joong Yoon, Sung-Sik Yoo, Jong-Hyeon Park, Jong-Soo Lee

    Foot-and-mouth disease (FMD) is a highly contagious and economically devastating disease in cloven-hoofed animals. To prevent the spread of FMD virus (FMDV), traditional inactivated vaccines are used to immunize susceptible animals in disease-endemic countries. However, the inactivated FMD vaccine has several limitations, including safety concerns. To overcome these limitations, subunit proteins have been studied as alternative vaccine candidates. In this study, we designed two multiepitope recombinant proteins (OVM and AVM) containing antigenic sites (residue of VP1 132–162 and residue of VP1 192–212) of three topotypes of FMDV serotype O or three topotypes of FMDV serotype A. Each recombinant protein was efficiently expressed in Escherichia coli with high solubility, and the immunogenicity and protective efficacy of the proteins as FMD vaccine candidates were evaluated. The results showed that OVM and AVM emulsified with ISA201 adjuvant induced effective antigen-specific humoral and cell-mediated immune responses and successfully protected mice from O/Jincheon/SKR/2014, O/VET/2013, and A/Malaysia/97 viruses. In addition, intramuscular immunization of pigs with the OVM and AVM emulsified with ISA201 elicited effective levels of neutralizing antibodies to the viruses with homologous epitopes. Importantly, OVM-AVM emulsified with CAvant®SOE-X adjuvant conferred 100% protection against the O/Jincheon/SKR/2014 virus with homologous residues and 75% protection against A/SKR/GP/2018 with heterologous residues. The results presented in this study suggest that the combination of OVM and AVM protein with an effective adjuvant could yield an effective and safe vaccine candidate for the prevention and control of foot-and-mouth disease. In addition, our results provide a vaccine platform that can safely, cost-efficiently, and rapidly generate protective vaccine candidates against diverse FMDVs.


  • Open Access

    CAvant® WO-60 as an Effective Immunological Adjuvant for Avian Influenza and Newcastle Disease Vaccine

    by Eun-Seo Lee, Young-Jung Shim, W. A. Gayan Chathuranga, Young-Hoon Ahn, In-Joong Yoon, Sung-Sik Yoo, Jong-Soo Lee

    Despite the immunogenicity of vaccines currently used in poultry, several pathogens, including avian influenza virus (AIV) and Newcastle disease virus (NDV), cause enormous economic losses to the global poultry industry. The efficacy of vaccines can be improved by the introduction of effective adjuvants. This study evaluated a novel water-in-oil emulsion adjuvant, CAvant® WO-60, which effectively enhanced both the immunogenicity of conserved influenza antigen sM2HA2 and inactivated whole H9N2 antigen (iH9N2). CAvant® WO-60 induced both humoral and cell-mediated immunity in mice and provided 100% protection from challenge with 10 LD50 of A/Aquatic bird/Korea/W81/2005 (H5N2) and A/Chicken/Korea/116/2004 (H9N2) AIV. Importantly, immunization of chickens with iH9N2 plus inactivated NDV LaSota (iNDV) bivalent inactivated vaccine emulsified in CAvant® WO-60 induced seroprotective levels of antigen-specific antibody responses. Taken together, these results suggested that CAvant® WO-60 is a promising adjuvant for poultry vaccines.


  • Open Access

    The Potential Adjuvanticity of CAvant®SOE for Foot-and-Mouth Disease Vaccine

    by Young-Hoon Ahn, W. A. Gayan Chathuranga, Young-Jung Shim, D. K. Haluwana, Eun-Hee Kim, In-Joong Yoon, Yong-Taik Lim, Sung Ho Shin, Hyundong Jo, Seong Yun Hwang, et al.

    Foot-and-mouth disease (FMD) is a notifiable contagious disease of cloven-hoofed mammals. A high potency vaccine that stimulates the host immune response is the foremost strategy used to prevent disease persistence in endemic regions. FMD vaccines comprise inactivated virus antigens whose immunogenicity is potentiated by immunogenic adjuvants. Oil-based adjuvants have clear advantages over traditional adjuvant vaccines; however, there is potential to develop novel adjuvants to increase the potency of FMD vaccines. Thus, we aimed to evaluate the efficacy of a novel water-in-oil emulsion, called CAvant®SOE, as a novel vaccine adjuvant for use with inactivated FMD vaccines. In this study, we found that inactivated A22 Iraq virus plus CAvant®SOE (iA22 Iraq-CAvant®SOE) induced effective antigen-specific humoral (IgG, IgG1, and IgG2a) and cell-mediated immune responses (IFN-γ and IL-4) in mice. Immunization of pigs with a single dose of iA22 Iraq-CAvant®SOE also elicited effective protection, with no detectable clinical symptoms against challenge with heterologous A/SKR/GP/2018 FMDV. Levels of protection are strongly in line with vaccine-induced neutralizing antibody titers. Collectively, these results indicate that CAvant®SOE-adjuvanted vaccine is a promising candidate for control of FMD in pigs.